Skip to content

Harrow HROW Accrued compensation and employee benefits

Accrued compensation and employee benefits at other companies

Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.59B+38.4%

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities.

The official record: Harrow’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's accrued compensation and employee benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harrow's accrued compensation and employee benefits?
Harrow (HROW) reported accrued compensation and employee benefits of -$1.2M in Q1 2026.
How has Harrow's accrued compensation and employee benefits changed year-over-year?
Harrow's accrued compensation and employee benefits increased by 36.5% year-over-year, from -$1.89M to -$1.2M.
What is the long-term trend for Harrow's accrued compensation and employee benefits?
Over 4 years (2021 to 2025), Harrow's accrued compensation and employee benefits has grown at a 4.9% compound annual growth rate (CAGR), from $774K to $936K.